US20240023808A1 - Intraocular pressure sensing material, devices, and uses thereof - Google Patents
Intraocular pressure sensing material, devices, and uses thereof Download PDFInfo
- Publication number
- US20240023808A1 US20240023808A1 US18/375,595 US202318375595A US2024023808A1 US 20240023808 A1 US20240023808 A1 US 20240023808A1 US 202318375595 A US202318375595 A US 202318375595A US 2024023808 A1 US2024023808 A1 US 2024023808A1
- Authority
- US
- United States
- Prior art keywords
- pressure
- responsive material
- chromogenic
- color
- implant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004410 intraocular pressure Effects 0.000 title claims abstract description 23
- 239000011540 sensing material Substances 0.000 title description 3
- 239000000463 material Substances 0.000 claims abstract description 89
- 239000007943 implant Substances 0.000 claims abstract description 53
- 230000004044 response Effects 0.000 claims abstract description 10
- 239000004038 photonic crystal Substances 0.000 claims description 32
- 230000008859 change Effects 0.000 claims description 20
- 208000010412 Glaucoma Diseases 0.000 claims description 19
- 229920000431 shape-memory polymer Polymers 0.000 claims description 16
- 230000004406 elevated intraocular pressure Effects 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 239000000017 hydrogel Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 28
- 241001465754 Metazoa Species 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 201000010099 disease Diseases 0.000 description 15
- 238000011282 treatment Methods 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 8
- 206010030043 Ocular hypertension Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 241000282465 Canis Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- ZDQNWDNMNKSMHI-UHFFFAOYSA-N 1-[2-(2-prop-2-enoyloxypropoxy)propoxy]propan-2-yl prop-2-enoate Chemical compound C=CC(=O)OC(C)COC(C)COCC(C)OC(=O)C=C ZDQNWDNMNKSMHI-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- UHESRSKEBRADOO-UHFFFAOYSA-N ethyl carbamate;prop-2-enoic acid Chemical class OC(=O)C=C.CCOC(N)=O UHESRSKEBRADOO-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
- A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
- A61B3/16—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for measuring intraocular pressure, e.g. tonometers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
- A61B5/686—Permanently implanted devices, e.g. pacemakers, other stimulators, biochips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
- A61F2/16—Intraocular lenses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0081—Prosthesis for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
- A61M2205/584—Means for facilitating use, e.g. by people with impaired vision by visual feedback having a color code
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M25/0045—Catheters; Hollow probes characterised by structural features multi-layered, e.g. coated
Definitions
- Measurement of intraocular pressure is important for glaucoma and many eye diseases.
- indirect methods are used for measuring intraocular pressure which involve external contact to the eye.
- the results are variable based upon the corneal thickness and other structural differences in the wall of the eye. As such, there exists a need for improved eye monitoring devices and techniques.
- Intraocular implants as described herein can comprise a pressure-responsive material, the pressure-responsive material comprising chromogenic photonic crystals, wherein the chromogenic photonic crystals change confirmation resulting in a change of color of the pressure-responsive material in response to an amount of pressure exerted on the shape-memory chromogenic photonic crystals.
- the pressure-responsive material can be a first color at a normal physiologic intraocular pressure of about 10 to about 20 mm Hg.
- the pressure-responsive material can be second color at an elevated intraocular pressure of greater than about 20 mm Hg.
- the pressure-responsive material can be a third color at a reduced intraocular pressure of less than about 10 mm Hg.
- the implant can be an intraocular lens. In embodiments according to the present disclosure, the implant can be a glaucoma drainage device.
- the pressure responsive material can be coated on a surface of a drainage tube of the glaucoma drainage device.
- the surface can be an outer surface of the drainage tube. In embodiments according to the present disclosure, the surface can be an inner surface of the drainage tube.
- the implant can comprise one or more layers of the pressure-responsive material coated on all or part of a surface of the implant or component thereof.
- each of the one or more layers is about 0.5 mm to about 3 mm thick.
- the pressure-responsive material can be integrated with a component of the implant.
- the implant can comprise one or more layers of the pressure-responsive material embedded in all or part of a surface of the implant or component thereof. In other embodiments, the implant can include the pressure-responsive material in the body of the implant.
- the pressure responsive material can comprise photonic crystals embedded in (e.g. encapsulated in) a hydrogel.
- methods as described herein comprise: implanting into the eye of a subject in need thereof an implant according to the present disclosure.
- methods can further comprise detecting the color of the pressure-responsive material of the implant without contacting the eye.
- methods can further comprise quantitatively measuring the color of the pressure-responsive material of the implant using a spectrometer.
- a subject in need thereof can be a human or a canine.
- the subject in need thereof has or is at risk for ocular hypertension.
- the subject in need thereof has glaucoma.
- a method of measuring intraocular pressure in a subject having an implant comprising: detecting the color of the pressure-responsive material of the implant without contacting the eye.
- the subject can be a human or a canine.
- the subject can have ocular hypertension or can be at risk for ocular hypertension.
- the subject in need thereof can have glaucoma.
- methods as described herein can comprise quantitatively measuring the color of the pressure-responsive material of the implant using a spectrometer or other spectral monitoring device, for example a smartphone with an application configured for spectrometry.
- Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of molecular biology, microbiology, organic chemistry, biochemistry, physiology, cell biology, cancer biology, and the like, which are within the skill of the art. Such techniques are explained fully in the literature.
- biocompatible refers to a material that along with any metabolites or degradation products thereof that are generally non-toxic to the recipient and do not cause any significant adverse effects to the recipient.
- biocompatible materials are materials that do not elicit a significant inflammatory or immune response when administered to a patient.
- organism refers to any living entity comprised of at least one cell.
- a living organism can be as simple as, for example, a single isolated eukaryotic cell or cultured cell or cell line, or as complex as a mammal, including a human being, and animals (e.g., vertebrates, amphibians, fish, mammals, e.g., cats, dogs, horses, pigs, cows, sheep, rodents, rabbits, squirrels, bears, primates (e.g., chimpanzees, gorillas, and humans).
- animals e.g., vertebrates, amphibians, fish, mammals, e.g., cats, dogs, horses, pigs, cows, sheep, rodents, rabbits, squirrels, bears, primates (e.g., chimpanzees, gorillas, and humans).
- the terms “treating” and “treatment” can refer generally to obtaining a desired pharmacological and/or physiological effect.
- the effect can be, but does not necessarily have to be, prophylactic in terms of preventing or partially preventing a disease, symptom or condition thereof, such as abnormal eye pressure and/or diseases and conditions associated with abnormal eye pressure (including but not limited to glaucoma).
- the effect can be therapeutic in terms of a partial or complete cure of a disease, condition, symptom or adverse effect attributed to the disease, disorder, or condition.
- treatment covers any treatment of glaucoma, ocular hypertension (elevated intraocular eye pressure), or reduced intraocular eye pressure, in a subject, particularly a human or a canine, and can include any one or more of the following: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., mitigating or ameliorating the disease and/or its symptoms or conditions.
- treatment as used herein can refer to both therapeutic treatment alone, prophylactic treatment alone, or both therapeutic and prophylactic treatment.
- Those in need of treatment can include those already with the disorder and/or those in which the disorder is to be prevented.
- the term “treating”, can include inhibiting the disease, disorder or condition, e.g., impeding its progress; and relieving the disease, disorder, or condition, e.g., causing regression of the disease, disorder and/or condition.
- Treating the disease, disorder, or condition can include ameliorating at least one symptom of the particular disease, disorder, or condition, even if the underlying pathophysiology is not affected, such as treating the pain of a subject by administration of an analgesic agent even though such agent does not treat the cause of the pain.
- Measurement of intraocular pressure is important for diagnosis and treatment of glaucoma and many other eye diseases.
- indirect methods are used for measuring intraocular eye pressure. These methods involve external eye contact to the eye.
- current methodologies produce results that are variable and based upon the corneal thickness and other structural differences in the wall in the eye that can change over time. As such, current methodologies can produce inaccurate results which can negatively impact eye health evaluations and disease monitoring and treatment.
- materials which can be biocompatible, that can be pressure-responsive and incorporated in intraocular lenses and/or other eye devices that can be capable of monitoring eye pressure.
- the materials can be capable of changing color in response to pressure exerted on the material.
- the color of the material can be quantitatively measured and can provide a direct and non-contact method of measuring intraocular pressure.
- Described herein are devices that can be implanted into a subject, such as in the eye or eye region, that can include a pressure-responsive material.
- the pressure responsive material can be composed of chromogenic photonic crystals that can be based on smart shape memory polymers.
- the chromogenic photonic crystals can be as described in Leo, S. et al. 2018. Chromogenic Photonic Crystal Sensors Enabled by Multistimuli-Responsive Shape Memory Polymers” Small 14(12):1703515, which is incorporated by reference as if fully set forth herein.
- chromogenic photonic crystal sensors are based on smart shape memory polymers (SMPs) comprising polyester/polyether-based urethane acrylates blended with tripropylene glycol diacrylate, which exhibit nontraditional all-room-temperature shape memory (SM) effects.
- SMPs smart shape memory polymers
- SM shape memory
- the pressure-responsive material can change color when different pressures are exerted on it.
- the intraocular pressure can be exerted on the pressure-responsive material incorporated in the device.
- the pressure-responsive material can change confirmation depending on the amount of pressure exerted on it by the eye contents and thus be a particular color depending on that exerted pressure.
- the color can be qualitatively measured by shining a light into the eye and onto the pressure-responsive material implanted in the eye and observing the color of the pressure-responsive material.
- the color can be measured quantitatively using spectral analysis to determine the color of the pressure-responsive material. Any suitable device that can externally measure the color spectrally can be used.
- the device is a hand held spectrometer or smartphone with an imaging device.
- an imaging device Such devices are generally known and available.
- a color analysis app e.g., Color Mate Version 1.2.2
- installed on a smartphone can be used in analyzing the RGB values of the sensor in response to different intraocular pressures.
- the color of the pressure-responsive material can be tuned by including silica particles with different diameters.
- the pressure-responsive materials of the present disclosure and devices including the pressure-responsive material can cover the whole visible spectrum range from 400 to 700 nm.
- the material can appear green, blue, and red, respectively.
- the visible color can correlate to a pressure.
- the color of the pressure-responsive material can be directly correlated to the intraocular pressure.
- the color of the pressure-responsive material can range from about 500 nm to 550 nm corresponding to a green color.
- the color of the pressure-responsive material can range be a first color.
- An intraocular pressure that is above normal (elevated intraocular eye pressure) can be anything over about 20 mm Hg.
- the color of the pressure-responsive material can be a second color that is different from that at normal physiological pressure.
- the color of the pressure-responsive material can range from about 400 nm to 450 nm corresponding to a blue color. If a subject is not having symptoms of an eye disease such as glaucoma but has an elevated intraocular pressure, this can be referred to as ocular hypertension. These individuals are at risk for developing an eye disease, such as glaucoma, and can require more intensive monitoring.
- Ocular hypertension is not the only pressure abnormality that can lead to eye problems.
- the intraocular pressure can become too low.
- a condition called hypotony can be diagnosed if the intraocular pressure decreases to about 6 mm Hg or less or in some cases about 10 mm Hg or less.
- intraocular pressure is too low it can cause distortions of the retina, lens, and cornea that can degrade vision and lead to vision loss.
- the color of the pressure-responsive material can be a third color that is different than the color at normal physiological pressure or elevated pressure.
- the color of the pressure-responsive material can range from about 600 nm to 650 nm corresponding to a red color.
- the pressure-responsive material can be coated in one or more layers on or incorporated into at least a portion of an implantable intraocular device.
- the pressure-responsive material can be coated on or incorporated into at least a portion of an intraocular lens or other prosthetic devices.
- a layer of the pressure-responsive material can range from about 0.1 mm to 0.5 mm, 0.5 mm to about 3 mm, about 1 mm to about 2.5 mm, about 1.5 mm to about 2 mm thick.
- Suitable intraocular lenses and prosthetics are generally known and available.
- the implantable device can include the pressure-responsive material in the body of the implant.
- the pressure-responsive material could be placed in the outer part of the optic, thus leaving the central visual axis clear of any color change or potentially different refractive index material to prevent or minimize visual clarity issues while still undergoing pressure-responsive color change.
- Glaucoma can be treated by implanting a device that helps keep the surgically-created drainage opening from healing and closing down. Many incorporate a tube through which the aqueous eye fluid passes. Others are solid and promote the flow of fluid along the surface of the implant. Newer implants commonly referred to as micro-invasive glaucoma surgery devices are tiny drainage implants (e.g. the Cypass Microstent from Alcon, AqueSys's XEN Gel Stent, MicroShunt Glaucoma Drainage System by InnFocus Inc., STARflo Glaucoma Implant and MlNlject from iSTar Madical SA, and the Hydrus Microstent form Ivantis) have also been developed and incorporate tiny drainage conduits (e.g.
- the pressure-responsive material can be coated on or incorporated in any of the components of an implant for treatment of glaucoma. In some aspects the pressures-responsive material can be incorporated on or on the inside of the drainage stent or tube of the implant.
- the pressure-responsive material can be coated on an existing eye implant device described above.
- the pressure-responsive material can be coated on or otherwise incorporated in an eye implant device at the point of manufacture of the device or any of its components or material.
- the eye implant device can be inserted into an eye of a subject using any suitable surgical technique that is appropriate for that particular eye implant and subject. This can be determined by the medical practitioner.
- the pressure of the subject's eye containing the eye implant device can be measured qualitatively by viewing the color of the pressure-responsive material using suitable eye examination devices and equipment (e.g. ophthalmoscope, ophthalmic lope, otoscopes, etc.) and/or qualitatively by using a suitable spectrophotometer device. These are discussed elsewhere herein.
- the method of pressure measurement when the pressure-responsive material and devices incorporating the pressure-responsive material is employed does not require contact with the eye or subject to changes in the structures of the eye. Further, this measurement method does not require any eye dilation or other uncomfortable procedures to allow measurement. Further, the devices herein allow for measurement of eye pressure at any time. This can be an advantage of current techniques as the pressure of the eye can change throughout the day. The devices and techniques described herein can thus allow for improved monitoring of the eye, particularly a diseased eye, and improve care of the subject.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Vascular Medicine (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
Abstract
Described herein are eye implants that can include a pressure-responsive material that can be capable of changing color in response to pressure exerted on it. Also described here are methods of implanting and using the eye implants described herein to monitor intraocular pressure in a subject. The pressure-responsive material can be used to diagnose and monitor human or animal subjects.
Description
- This application is a continuation of U.S. patent application Ser. No. 17/051,051, having the title “INTRAOCULAR PRESSURE SENSING MATERIAL, DEVICES, AND USES THEREOF”, filed on Oct. 27, 2020, which is the 35 U.S.C. § 371 national stage application of PCT Application No. PCT/US2019/038193, filed Jun. 20, 2019, where the PCT claims priority to, and the benefit of, U.S. provisional application entitled “INTRAOCULAR PRESSURE SENSING MATERIAL, DEVICES, AND USES THEREOF” having Ser. No. 62/687,614, filed Jun. 20, 2018, both of which are herein incorporated by reference in their entireties.
- This invention was made with Government support under HDTRA-1-15-1-0022 awarded by the Department of Defense/Defense Threat Reduction Agency. The Government has certain rights in this invention.
- Measurement of intraocular pressure is important for glaucoma and many eye diseases. Currently, indirect methods are used for measuring intraocular pressure which involve external contact to the eye. However, the results are variable based upon the corneal thickness and other structural differences in the wall of the eye. As such, there exists a need for improved eye monitoring devices and techniques.
- In embodiments of the present disclosure, disclosed herein are intraocular implants. Intraocular implants as described herein can comprise a pressure-responsive material, the pressure-responsive material comprising chromogenic photonic crystals, wherein the chromogenic photonic crystals change confirmation resulting in a change of color of the pressure-responsive material in response to an amount of pressure exerted on the shape-memory chromogenic photonic crystals.
- In embodiments according to the present disclosure, the pressure-responsive material can be a first color at a normal physiologic intraocular pressure of about 10 to about 20 mm Hg. The pressure-responsive material can be second color at an elevated intraocular pressure of greater than about 20 mm Hg. The pressure-responsive material can be a third color at a reduced intraocular pressure of less than about 10 mm Hg.
- In embodiments according to the present disclosure, the implant can be an intraocular lens. In embodiments according to the present disclosure, the implant can be a glaucoma drainage device.
- In embodiments according to the present disclosure, the pressure responsive material can be coated on a surface of a drainage tube of the glaucoma drainage device.
- In embodiments according to the present disclosure, the surface can be an outer surface of the drainage tube. In embodiments according to the present disclosure, the surface can be an inner surface of the drainage tube.
- In embodiments according to the present disclosure, the implant can comprise one or more layers of the pressure-responsive material coated on all or part of a surface of the implant or component thereof.
- In embodiments according to the present disclosure, each of the one or more layers is about 0.5 mm to about 3 mm thick.
- In embodiments according to the present disclosure, the pressure-responsive material can be integrated with a component of the implant.
- In embodiments according to the present disclosure, the implant can comprise one or more layers of the pressure-responsive material embedded in all or part of a surface of the implant or component thereof. In other embodiments, the implant can include the pressure-responsive material in the body of the implant.
- In embodiments according to the present disclosure, the pressure responsive material can comprise photonic crystals embedded in (e.g. encapsulated in) a hydrogel.
- Also described herein are methods. In embodiments according to the present disclosure, methods as described herein comprise: implanting into the eye of a subject in need thereof an implant according to the present disclosure.
- In embodiments according to the present disclosure, methods can further comprise detecting the color of the pressure-responsive material of the implant without contacting the eye.
- In embodiments according to the present disclosure, methods can further comprise quantitatively measuring the color of the pressure-responsive material of the implant using a spectrometer.
- In embodiments according to the present disclosure, a subject in need thereof can be a human or a canine. In embodiments according to the present disclosure, the subject in need thereof has or is at risk for ocular hypertension. In embodiments according to the present disclosure, the subject in need thereof has glaucoma.
- In embodiments according to the present disclosure, a method of measuring intraocular pressure in a subject having an implant is described herein, the method comprising: detecting the color of the pressure-responsive material of the implant without contacting the eye. The subject can be a human or a canine. The subject can have ocular hypertension or can be at risk for ocular hypertension. The subject in need thereof can have glaucoma.
- In embodiments according to the present disclosure, methods as described herein can comprise quantitatively measuring the color of the pressure-responsive material of the implant using a spectrometer or other spectral monitoring device, for example a smartphone with an application configured for spectrometry.
- Before the present disclosure is described in greater detail, it is to be understood that this disclosure is not limited to particular embodiments described, and as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
- Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described.
- All publications and patents cited in this specification are cited to disclose and describe the methods and/or materials in connection with which the publications are cited. All such publications and patents are herein incorporated by references as if each individual publication or patent were specifically and individually indicated to be incorporated by reference. Such incorporation by reference is expressly limited to the methods and/or materials described in the cited publications and patents and does not extend to any lexicographical definitions from the cited publications and patents. Any lexicographical definition in the publications and patents cited that is not also expressly repeated in the instant application should not be treated as such and should not be read as defining any terms appearing in the accompanying claims. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided could be different from the actual publication dates that may need to be independently confirmed.
- As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.
- Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of molecular biology, microbiology, organic chemistry, biochemistry, physiology, cell biology, cancer biology, and the like, which are within the skill of the art. Such techniques are explained fully in the literature.
- As used herein, “about,” “approximately,” and the like, when used in connection with a numerical variable, can generally refers to the value of the variable and to all values of the variable that are within the experimental error (e.g., within the 95% confidence interval for the mean) or within +/−10% of the indicated value, whichever is greater.
- The term “biocompatible”, as used herein, refers to a material that along with any metabolites or degradation products thereof that are generally non-toxic to the recipient and do not cause any significant adverse effects to the recipient. Generally speaking, biocompatible materials are materials that do not elicit a significant inflammatory or immune response when administered to a patient.
- As used herein, “organism”, “host”, and “subject” refers to any living entity comprised of at least one cell. A living organism can be as simple as, for example, a single isolated eukaryotic cell or cultured cell or cell line, or as complex as a mammal, including a human being, and animals (e.g., vertebrates, amphibians, fish, mammals, e.g., cats, dogs, horses, pigs, cows, sheep, rodents, rabbits, squirrels, bears, primates (e.g., chimpanzees, gorillas, and humans).
- As used herein, the terms “treating” and “treatment” can refer generally to obtaining a desired pharmacological and/or physiological effect. The effect can be, but does not necessarily have to be, prophylactic in terms of preventing or partially preventing a disease, symptom or condition thereof, such as abnormal eye pressure and/or diseases and conditions associated with abnormal eye pressure (including but not limited to glaucoma). The effect can be therapeutic in terms of a partial or complete cure of a disease, condition, symptom or adverse effect attributed to the disease, disorder, or condition. The term “treatment” as used herein covers any treatment of glaucoma, ocular hypertension (elevated intraocular eye pressure), or reduced intraocular eye pressure, in a subject, particularly a human or a canine, and can include any one or more of the following: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., mitigating or ameliorating the disease and/or its symptoms or conditions. The term “treatment” as used herein can refer to both therapeutic treatment alone, prophylactic treatment alone, or both therapeutic and prophylactic treatment. Those in need of treatment (subjects in need thereof) can include those already with the disorder and/or those in which the disorder is to be prevented. As used herein, the term “treating”, can include inhibiting the disease, disorder or condition, e.g., impeding its progress; and relieving the disease, disorder, or condition, e.g., causing regression of the disease, disorder and/or condition. Treating the disease, disorder, or condition can include ameliorating at least one symptom of the particular disease, disorder, or condition, even if the underlying pathophysiology is not affected, such as treating the pain of a subject by administration of an analgesic agent even though such agent does not treat the cause of the pain.
- Discussion
- Measurement of intraocular pressure is important for diagnosis and treatment of glaucoma and many other eye diseases. Currently, indirect methods are used for measuring intraocular eye pressure. These methods involve external eye contact to the eye. Thus, current methodologies produce results that are variable and based upon the corneal thickness and other structural differences in the wall in the eye that can change over time. As such, current methodologies can produce inaccurate results which can negatively impact eye health evaluations and disease monitoring and treatment.
- With that said, described herein are materials, which can be biocompatible, that can be pressure-responsive and incorporated in intraocular lenses and/or other eye devices that can be capable of monitoring eye pressure. The materials can be capable of changing color in response to pressure exerted on the material. The color of the material can be quantitatively measured and can provide a direct and non-contact method of measuring intraocular pressure. Other compositions, compounds, methods, features, and advantages of the present disclosure will be or become apparent to one having ordinary skill in the art upon examination of the following drawings, detailed description, and examples. It is intended that all such additional compositions, compounds, methods, features, and advantages be included within this description, and be within the scope of the present disclosure.
- Described herein are devices that can be implanted into a subject, such as in the eye or eye region, that can include a pressure-responsive material. The pressure responsive material can be composed of chromogenic photonic crystals that can be based on smart shape memory polymers. The chromogenic photonic crystals can be as described in Leo, S. et al. 2018. Chromogenic Photonic Crystal Sensors Enabled by Multistimuli-Responsive Shape Memory Polymers” Small 14(12):1703515, which is incorporated by reference as if fully set forth herein. In embodiments according to the present disclosure, chromogenic photonic crystal sensors are based on smart shape memory polymers (SMPs) comprising polyester/polyether-based urethane acrylates blended with tripropylene glycol diacrylate, which exhibit nontraditional all-room-temperature shape memory (SM) effects.
- The pressure-responsive material can change color when different pressures are exerted on it. Thus, when incorporated in a device that is implanted into an eye, the intraocular pressure can be exerted on the pressure-responsive material incorporated in the device. The pressure-responsive material can change confirmation depending on the amount of pressure exerted on it by the eye contents and thus be a particular color depending on that exerted pressure. The color can be qualitatively measured by shining a light into the eye and onto the pressure-responsive material implanted in the eye and observing the color of the pressure-responsive material. The color can be measured quantitatively using spectral analysis to determine the color of the pressure-responsive material. Any suitable device that can externally measure the color spectrally can be used. In some aspects, the device is a hand held spectrometer or smartphone with an imaging device. Such devices are generally known and available. For example, a color analysis app (e.g., Color Mate Version 1.2.2) installed on a smartphone can be used in analyzing the RGB values of the sensor in response to different intraocular pressures.
- The color of the pressure-responsive material can be tuned by including silica particles with different diameters. Experiments have confirmed that the pressure-responsive materials of the present disclosure and devices including the pressure-responsive material can cover the whole visible spectrum range from 400 to 700 nm. For example, by including silica particles having an average diameter of about 500 to 500 nm, about 400 to 450 nm, and about 600 to 650 nm in the same pressure-responsive material, the material can appear green, blue, and red, respectively. The visible color can correlate to a pressure.
- The color of the pressure-responsive material can be directly correlated to the intraocular pressure. In some aspects, at normal physiologic intraocular pressure (about 10 to about 20 mm Hg) the color of the pressure-responsive material can range from about 500 nm to 550 nm corresponding to a green color. The color of the pressure-responsive material can range be a first color. An intraocular pressure that is above normal (elevated intraocular eye pressure) can be anything over about 20 mm Hg. At elevated intraocular pressures ranging from about 20 mm Hg to about 30 mm Hg or more, the color of the pressure-responsive material can be a second color that is different from that at normal physiological pressure. The color of the pressure-responsive material can range from about 400 nm to 450 nm corresponding to a blue color. If a subject is not having symptoms of an eye disease such as glaucoma but has an elevated intraocular pressure, this can be referred to as ocular hypertension. These individuals are at risk for developing an eye disease, such as glaucoma, and can require more intensive monitoring.
- Ocular hypertension is not the only pressure abnormality that can lead to eye problems. In some cases, such as after eye surgery (e.g. glaucoma surgery) or episodes of ocular ischemia, the intraocular pressure can become too low. A condition called hypotony can be diagnosed if the intraocular pressure decreases to about 6 mm Hg or less or in some cases about 10 mm Hg or less. When intraocular pressure is too low it can cause distortions of the retina, lens, and cornea that can degrade vision and lead to vision loss. At reduced intraocular pressures ranging from about 4 mm Hg to about 10 mm Hg, the color of the pressure-responsive material can be a third color that is different than the color at normal physiological pressure or elevated pressure. The color of the pressure-responsive material can range from about 600 nm to 650 nm corresponding to a red color.
- As described above, the pressure-responsive material can be coated in one or more layers on or incorporated into at least a portion of an implantable intraocular device. The pressure-responsive material can be coated on or incorporated into at least a portion of an intraocular lens or other prosthetic devices. In some aspects, a layer of the pressure-responsive material can range from about 0.1 mm to 0.5 mm, 0.5 mm to about 3 mm, about 1 mm to about 2.5 mm, about 1.5 mm to about 2 mm thick. Suitable intraocular lenses and prosthetics are generally known and available.
- The implantable device can include the pressure-responsive material in the body of the implant. In the case of an intra-ocular lens implant, for example, the pressure-responsive material could be placed in the outer part of the optic, thus leaving the central visual axis clear of any color change or potentially different refractive index material to prevent or minimize visual clarity issues while still undergoing pressure-responsive color change.
- Glaucoma can be treated by implanting a device that helps keep the surgically-created drainage opening from healing and closing down. Many incorporate a tube through which the aqueous eye fluid passes. Others are solid and promote the flow of fluid along the surface of the implant. Newer implants commonly referred to as micro-invasive glaucoma surgery devices are tiny drainage implants (e.g. the Cypass Microstent from Alcon, AqueSys's XEN Gel Stent, MicroShunt Glaucoma Drainage System by InnFocus Inc., STARflo Glaucoma Implant and MlNlject from iSTar Madical SA, and the Hydrus Microstent form Ivantis) have also been developed and incorporate tiny drainage conduits (e.g. stents) that can create a permanent conduits for moving eye fluids and decreasing intraocular pressure. Other various implants for treatment of glaucoma are known. The pressure-responsive material can be coated on or incorporated in any of the components of an implant for treatment of glaucoma. In some aspects the pressures-responsive material can be incorporated on or on the inside of the drainage stent or tube of the implant.
- In use, the pressure-responsive material can be coated on an existing eye implant device described above. In other aspects, the pressure-responsive material can be coated on or otherwise incorporated in an eye implant device at the point of manufacture of the device or any of its components or material. The eye implant device can be inserted into an eye of a subject using any suitable surgical technique that is appropriate for that particular eye implant and subject. This can be determined by the medical practitioner. After implantation, the pressure of the subject's eye containing the eye implant device can be measured qualitatively by viewing the color of the pressure-responsive material using suitable eye examination devices and equipment (e.g. ophthalmoscope, ophthalmic lope, otoscopes, etc.) and/or qualitatively by using a suitable spectrophotometer device. These are discussed elsewhere herein. The method of pressure measurement when the pressure-responsive material and devices incorporating the pressure-responsive material is employed does not require contact with the eye or subject to changes in the structures of the eye. Further, this measurement method does not require any eye dilation or other uncomfortable procedures to allow measurement. Further, the devices herein allow for measurement of eye pressure at any time. This can be an advantage of current techniques as the pressure of the eye can change throughout the day. The devices and techniques described herein can thus allow for improved monitoring of the eye, particularly a diseased eye, and improve care of the subject.
- Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs. Publications cited herein and the materials for which they are cited are specifically incorporated by reference.
- Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
Claims (13)
1. An intraocular implant comprising:
a pressure-responsive material, the pressure-responsive material comprising chromogenic photonic crystals, wherein the chromogenic photonic crystals change conformation resulting in a change of color of the pressure-responsive material in response to an amount of pressure exerted on the shape-memory chromogenic photonic crystals and wherein the chromogenic photonic crystal comprise smart shape memory polymers (SMPs), wherein the implant is an intraocular lens.
2. The intraocular implant of claim 1 , wherein the pressure-responsive material is a first color at a normal physiologic intraocular pressure of about 10 to about 20 mm Hg, wherein the first color ranges from about 500 nm to 550 nm corresponding to a green color.
3. The intraocular implant of claim 2 , wherein the pressure-responsive material is a second color at an elevated intraocular pressure of greater than about 20 mm Hg, wherein the second color ranges from about 400 nm to 450 nm corresponding to a blue color.
4. The intraocular implant of claim 3 , wherein the pressure-responsive material is a third color at a reduced intraocular pressure of less than about 10 mm Hg, wherein the third color ranges from about 600 nm to 650 nm corresponding to a red color.
5. An intraocular implant comprising:
a pressure-responsive material, the pressure-responsive material comprising chromogenic photonic crystals, wherein the chromogenic photonic crystals change conformation resulting in a change of color of the pressure-responsive material in response to an amount of pressure exerted on the shape-memory chromogenic photonic crystals and wherein the chromogenic photonic crystal comprise smart shape memory polymers (SMPs), wherein the implant is a glaucoma drainage device.
6. The intraocular implant of claim 5 , wherein the pressure responsive material is coated on a surface of a drainage tube of the glaucoma drainage device.
7. The intraocular implant of claim 6 , wherein the surface is an outer surface of the drainage tube.
8. The intraocular implant of claim 6 , wherein the surface is an inner surface of the drainage tube.
9. An intraocular implant comprising:
a pressure-responsive material, the pressure-responsive material comprising chromogenic photonic crystals, wherein the chromogenic photonic crystals change conformation resulting in a change of color of the pressure-responsive material in response to an amount of pressure exerted on the shape-memory chromogenic photonic crystals and wherein the chromogenic photonic crystal comprise smart shape memory polymers (SMPs), wherein the implant comprises one or more layers of the pressure-responsive material embedded in all or part of a surface of the implant or component thereof.
10. An intraocular implant comprising:
a pressure-responsive material, the pressure-responsive material comprising chromogenic photonic crystals, wherein the chromogenic photonic crystals change conformation resulting in a change of color of the pressure-responsive material in response to an amount of pressure exerted on the shape-memory chromogenic photonic crystals and wherein the chromogenic photonic crystal comprise smart shape memory polymers (SMPs), wherein the implant comprises one or more layers of the pressure-responsive material coated on all or part of a surface of the implant or component thereof.
11. The intraocular implant of claim 10 , wherein each of the one or more layers is about 0.5 mm to about 3 mm thick.
12. An intraocular implant comprising:
a pressure-responsive material, the pressure-responsive material comprising chromogenic photonic crystals, wherein the chromogenic photonic crystals change conformation resulting in a change of color of the pressure-responsive material in response to an amount of pressure exerted on the shape-memory chromogenic photonic crystals and wherein the chromogenic photonic crystal comprise smart shape memory polymers (SMPs), wherein the pressure-responsive material is integrated with a component of the implant.
13. An intraocular implant comprising:
a pressure-responsive material, the pressure-responsive material comprising chromogenic photonic crystals, wherein the chromogenic photonic crystals change conformation resulting in a change of color of the pressure-responsive material in response to an amount of pressure exerted on the shape-memory chromogenic photonic crystals and wherein the chromogenic photonic crystal comprise smart shape memory polymers (SMPs), wherein the pressure-responsive material comprises a hydrogel.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/375,595 US20240023808A1 (en) | 2018-06-20 | 2023-10-02 | Intraocular pressure sensing material, devices, and uses thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862687614P | 2018-06-20 | 2018-06-20 | |
PCT/US2019/038193 WO2019246370A1 (en) | 2018-06-20 | 2019-06-20 | Intraocular pressure sensing material, devices, and uses thereof |
US202017051051A | 2020-10-27 | 2020-10-27 | |
US18/375,595 US20240023808A1 (en) | 2018-06-20 | 2023-10-02 | Intraocular pressure sensing material, devices, and uses thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/051,051 Continuation US11819277B2 (en) | 2018-06-20 | 2019-06-20 | Intraocular pressure sensing material, devices, and uses thereof |
PCT/US2019/038193 Continuation WO2019246370A1 (en) | 2018-06-20 | 2019-06-20 | Intraocular pressure sensing material, devices, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20240023808A1 true US20240023808A1 (en) | 2024-01-25 |
Family
ID=68984227
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/051,051 Active 2040-10-09 US11819277B2 (en) | 2018-06-20 | 2019-06-20 | Intraocular pressure sensing material, devices, and uses thereof |
US18/375,595 Pending US20240023808A1 (en) | 2018-06-20 | 2023-10-02 | Intraocular pressure sensing material, devices, and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/051,051 Active 2040-10-09 US11819277B2 (en) | 2018-06-20 | 2019-06-20 | Intraocular pressure sensing material, devices, and uses thereof |
Country Status (2)
Country | Link |
---|---|
US (2) | US11819277B2 (en) |
WO (1) | WO2019246370A1 (en) |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3422535A (en) | 1965-10-19 | 1969-01-21 | Unitek Corp | Dental shell crown |
US3671105A (en) | 1971-04-28 | 1972-06-20 | Nasa | Light regulator |
US4125319A (en) | 1976-05-03 | 1978-11-14 | Eastman Kodak Company | Active light control device |
NZ190436A (en) | 1978-05-15 | 1981-12-15 | Pall Corp | Preparation of skinless hydrophilic alcohol insoluble polyamide membranes membranes casting resin solutions |
US4781441A (en) | 1983-11-25 | 1988-11-01 | Canon Kabushiki Kaisha | Method of controlling orientation of liquid crystal, device used therein and liquid crystal device produced thereby |
US4810633A (en) | 1984-06-04 | 1989-03-07 | Miles Inc. | Enzymatic ethanol test |
JPS61108176A (en) | 1984-11-01 | 1986-05-26 | Fuji Electric Co Ltd | Method for coarsening surface |
JPH01165457U (en) | 1988-05-12 | 1989-11-20 | ||
US5147716A (en) | 1989-06-16 | 1992-09-15 | Minnesota Mining And Manufacturing Company | Multi-directional light control film |
NL9100217A (en) | 1991-02-07 | 1992-09-01 | Univ Delft Tech | MOLECULAR SCREEN CRYSTALS CONTAINING INORGANIC COMPOSITE MEMBRANE. |
US5337018A (en) | 1992-11-13 | 1994-08-09 | Hughes Aircraft Company | Electronic sensor for determining alcohol content of fuels |
JPH08507643A (en) | 1993-03-11 | 1996-08-13 | フェド.コーポレイション | Emitter tip structure, field emission device including the emitter tip structure, and method of manufacturing the same |
NL9401260A (en) | 1993-11-12 | 1995-06-01 | Cornelis Johannes Maria Van Ri | Membrane for microfiltration, ultrafiltration, gas separation and catalysis, method for manufacturing such a membrane, mold for manufacturing such a membrane, as well as various separation systems comprising such a membrane. |
US5798042A (en) | 1994-03-07 | 1998-08-25 | Regents Of The University Of California | Microfabricated filter with specially constructed channel walls, and containment well and capsule constructed with such filters |
US5939189A (en) | 1995-05-09 | 1999-08-17 | Flex Products, Inc. | Flexible plastic substrate with anti-reflection coating having low reflective color and method |
US5641332A (en) | 1995-12-20 | 1997-06-24 | Corning Incorporated | Filtraion device with variable thickness walls |
US6014246A (en) | 1996-11-06 | 2000-01-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Thermally switchable optical devices |
US5993661A (en) | 1997-04-14 | 1999-11-30 | The Research Foundation Of State University Of New York | Macroporous or microporous filtration membrane, method of preparation and use |
US5948470A (en) | 1997-04-28 | 1999-09-07 | Harrison; Christopher | Method of nanoscale patterning and products made thereby |
US7226966B2 (en) | 2001-08-03 | 2007-06-05 | Nanogram Corporation | Structures incorporating polymer-inorganic particle blends |
US7351470B2 (en) | 1998-02-19 | 2008-04-01 | 3M Innovative Properties Company | Removable antireflection film |
DE19821968A1 (en) | 1998-05-18 | 1999-11-25 | Studiengesellschaft Kohle Mbh | Production of transition metal colloid for use e.g. as coating, catalyst, fuel cell component and in ink jet printing, laser etching, information storage and cell labeling and cell separation |
AU5484499A (en) | 1998-08-18 | 2000-03-14 | Ppg Industries Ohio, Inc. | Process for producing durable antireflective surfaces and antireflective articles |
US6649255B1 (en) | 1999-03-04 | 2003-11-18 | Douglas E. Fain, Sr. | Article and method for producing extremely small pore inorganic membranes |
JP3940546B2 (en) | 1999-06-07 | 2007-07-04 | 株式会社東芝 | Pattern forming method and pattern forming material |
US7704750B2 (en) | 2000-06-21 | 2010-04-27 | Imbibitive Technologies Corp. | Visual spill indicator |
US6929764B2 (en) | 2000-11-17 | 2005-08-16 | William Marsh Rice University | Polymers having ordered, monodisperse pores and their corresponding ordered, monodisperse colloids |
KR100878281B1 (en) | 2001-03-14 | 2009-01-12 | 유니버시티 오브 매사츄세츠 | Nanofabrication |
US6881582B2 (en) | 2001-11-08 | 2005-04-19 | Council Of Scientific And Industrial Research | Thin film ethanol sensor and a process for the preparation |
US7813780B2 (en) | 2005-12-13 | 2010-10-12 | Medtronic Minimed, Inc. | Biosensors and methods for making and using them |
US7261920B2 (en) | 2002-04-24 | 2007-08-28 | Sipix Imaging, Inc. | Process for forming a patterned thin film structure on a substrate |
US20030232210A1 (en) | 2002-06-18 | 2003-12-18 | 3M Innovative Properties Company | Ink-receptive foam article |
US7449146B2 (en) | 2002-09-30 | 2008-11-11 | 3M Innovative Properties Company | Colorimetric sensor |
KR100460450B1 (en) | 2002-10-04 | 2004-12-08 | 한국화학연구원 | Preparation of the silica composite membranes with thermal stability by Soaking-Rolling method |
CA2501104C (en) | 2002-10-09 | 2011-11-29 | Andre Arsenault | Widely wavelength tuneable polychrome colloidal photonic crystal device |
US7826131B2 (en) | 2002-10-09 | 2010-11-02 | The Governing Council Of The University Of Toronto | Tunable photonic crystal device |
WO2004088130A1 (en) | 2003-03-31 | 2004-10-14 | Forskningscenter Risø | Control of power, loads and/or stability of a horizontal axis wind turbine by use of variable blade geometry control |
FR2857668B1 (en) * | 2003-07-16 | 2006-01-13 | Commissariat Energie Atomique | PHOTOPOLYMERIZABLE COMPOSITION BASED ON AN EXPOXYVINYLLESTER RESIN AND A URETHANE ACRYLATE RESIN AND THE USE OF SAID COMPOSITION FOR MAKING PREFORMS AND / OR DENTAL PROSTHESES. |
WO2005071479A1 (en) | 2004-01-21 | 2005-08-04 | Sharp Kabushiki Kaisha | Display and process for producing the same |
US7260999B2 (en) | 2004-12-23 | 2007-08-28 | 3M Innovative Properties Company | Force sensing membrane |
US20070228608A1 (en) | 2006-04-03 | 2007-10-04 | Molecular Imprints, Inc. | Preserving Filled Features when Vacuum Wiping |
US8033237B2 (en) | 2005-06-21 | 2011-10-11 | Cornerstone Research Group, Inc. | Environmental condition cumulative tracking integration sensor using shape memory polymer |
JP5096669B2 (en) | 2005-07-06 | 2012-12-12 | ルネサスエレクトロニクス株式会社 | Manufacturing method of semiconductor integrated circuit device |
WO2007035356A2 (en) * | 2005-09-16 | 2007-03-29 | Bg Implant, Inc. | Glaucoma treatment devices and methods |
JP4946016B2 (en) | 2005-11-25 | 2012-06-06 | 富士ゼロックス株式会社 | Multicolor display optical composition, optical element, and display method of optical element |
WO2008001670A1 (en) | 2006-06-30 | 2008-01-03 | Oji Paper Co., Ltd. | Monoparticulate-film etching mask and process for producing the same, process for producing fine structure with the monoparticulate-film etching mask, and fine structure obtained by the production process |
US7669719B2 (en) | 2006-07-05 | 2010-03-02 | General Electric Company | Membrane structure and method of making |
US20080027199A1 (en) | 2006-07-28 | 2008-01-31 | 3M Innovative Properties Company | Shape memory polymer articles with a microstructured surface |
US7691325B2 (en) | 2006-10-19 | 2010-04-06 | Xerox Corporation | Photonic crystal solvent vapor sensing device |
CA2928100C (en) | 2007-01-09 | 2017-07-04 | The Board Of Trustees Of The Leland Stanford Junior University | Photonic crystal stucture-based optical device and corresponding fabrication method |
US7682530B2 (en) | 2007-02-07 | 2010-03-23 | Sean Purdy | Crystalline colloidal arrays responsive to an activator |
US8676016B2 (en) | 2007-02-16 | 2014-03-18 | The Governing Council Of The University Of Toronto | Compressible photonic crystal |
US7943219B2 (en) | 2007-03-23 | 2011-05-17 | Kimberly-Clark Worldwide, Inc. | Films and articles with reversible opacity change upon stretching, and methods of making and using same |
EP2157976A4 (en) | 2007-04-19 | 2012-03-07 | Univ Massachusetts Medical | Thermal responsive polymer siloxanes, compositions, and methods and applications related thereto |
US20080309923A1 (en) | 2007-06-14 | 2008-12-18 | Falk R Aaron | Compact chemical sensor |
US20080317977A1 (en) | 2007-06-22 | 2008-12-25 | Chiefway Engineering Co., Ltd. | Light-regulation membrane |
US7889954B2 (en) | 2007-07-12 | 2011-02-15 | The Regents Of The University Of California | Optical fiber-mounted porous photonic crystals and sensors |
WO2009062140A2 (en) | 2007-11-08 | 2009-05-14 | Sager Brian M | Improved anti-reflective coating |
US20110097814A1 (en) | 2007-11-20 | 2011-04-28 | Bommarito G Marco | Detection devices and methods |
US8578761B2 (en) | 2008-03-26 | 2013-11-12 | Denso Corporation | Concentration sensor device and concentration detecting method |
US20100069726A1 (en) | 2008-06-04 | 2010-03-18 | Seventh Sense Biosystems, Inc. | Compositions and methods for rapid one-step diagnosis |
JP2010027802A (en) | 2008-07-17 | 2010-02-04 | Fujifilm Corp | Surface processing method, mask for surface processing, and optical device |
CA2731778C (en) | 2008-07-23 | 2017-04-25 | Opalux Incorporated | Tunable photonic crystal composition |
US8088439B2 (en) | 2008-08-29 | 2012-01-03 | Korea University Research And Business Foundation | Porous membrane and method of making the same |
US20100058844A1 (en) | 2008-09-11 | 2010-03-11 | Yingjie Lin | Ethanol concentration sensor |
EP2343733A1 (en) | 2008-09-19 | 2011-07-13 | FUJIFILM Corporation | Surface treatment mask, process for producing the surface treatment mask, method for surface treatment, particle-containing film, and process for producing the particle-containing film |
US8198349B2 (en) | 2008-11-18 | 2012-06-12 | GL Global Technology Operations LLC | Self-healing and scratch resistant shape memory polymer system |
US20100155325A1 (en) | 2008-12-24 | 2010-06-24 | General Electric Company | Particle-templated membranes, and related processes for their preparation |
US20100216310A1 (en) | 2009-02-20 | 2010-08-26 | Tokyo Electron Limited | Process for etching anti-reflective coating to improve roughness, selectivity and CD shrink |
TWI425643B (en) | 2009-03-31 | 2014-02-01 | Sony Corp | Solid-state imaging device, fabrication method thereof, imaging apparatus, and fabrication method of anti-reflection structure |
WO2010132996A1 (en) | 2009-05-22 | 2010-11-25 | University Of New Brunswick | Force sensing compositions, devices and methods |
US8252412B2 (en) | 2009-06-16 | 2012-08-28 | Ppg Industries Ohio, Inc | Angle switchable crystalline colloidal array films |
EP2488831A4 (en) | 2009-10-16 | 2013-05-08 | Opalux Inc | Photonic crystal combinatorial sensor |
CN102754217B (en) | 2009-11-17 | 2016-07-06 | 3M创新有限公司 | The textured surfaces of extinction base material |
US8120027B2 (en) | 2009-12-10 | 2012-02-21 | Leonard Forbes | Backside nanoscale texturing to improve IR response of silicon solar cells and photodetectors |
TW201204548A (en) | 2010-02-05 | 2012-02-01 | Sumitomo Bakelite Co | Prepreg, laminate, printed wiring board, and semiconductor device |
FR2956991B1 (en) | 2010-03-02 | 2012-11-02 | Commissariat Energie Atomique | METHOD FOR DEPOSITING A LAYER OF PARTICLES ORGANIZED ON A SUBSTRATE |
CN103025991A (en) | 2010-06-10 | 2013-04-03 | 哈佛大学校长及研究员协会 | Adaptive shading, display and color control |
KR101131485B1 (en) | 2010-08-02 | 2012-03-30 | 광주과학기술원 | Fabricating method of nano structure for antireflection and fabricating method of photo device integrated with antireflection nano structure |
WO2012021801A2 (en) | 2010-08-13 | 2012-02-16 | Seventh Sense Biosystems, Inc. | Systems and techniques for monitoring subjects |
US8983019B2 (en) | 2010-08-31 | 2015-03-17 | Massachusetts Institute Of Technology | Superwetting surfaces for diminishing leidenfrost effect, methods of making and devices incorporating the same |
US8795561B2 (en) | 2010-09-29 | 2014-08-05 | Milliken & Company | Process of forming a nanofiber non-woven containing particles |
US20130199995A1 (en) | 2010-10-27 | 2013-08-08 | University Of Florida Research Foundation Inc. | Porous polymer membranes, methods of making, and methods of use |
EP2646807B1 (en) | 2010-11-29 | 2022-07-20 | President and Fellows of Harvard College | Manipulation of fluids in three-dimensional porous photonic structures with patterned surface properties |
WO2012076612A1 (en) | 2010-12-08 | 2012-06-14 | Condalign As | Method for assembling conductive particles into conductive pathways and sensors thus formed |
WO2012087663A1 (en) | 2010-12-20 | 2012-06-28 | 3M Innovative Properties Company | Glass-like polymeric antireflective films coated with silica nanoparticles, methods of making and light absorbing devices using same |
KR101729304B1 (en) | 2010-12-21 | 2017-04-21 | 엘지전자 주식회사 | Solar cell and method for manufacturing the same |
JP2014512673A (en) | 2011-03-08 | 2014-05-22 | アライアンス フォー サステイナブル エナジー リミテッド ライアビリティ カンパニー | Efficient black silicon photovoltaic device with improved blue sensitivity |
EP2500314A1 (en) | 2011-03-14 | 2012-09-19 | Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO | Photonic crystal sensor |
US9074090B2 (en) | 2011-04-15 | 2015-07-07 | GM Global Technology Operations LLC | Shape memory polymer-based tunable photonic device |
US9272947B2 (en) | 2011-05-02 | 2016-03-01 | Corning Incorporated | Glass article having antireflective layer and method of making |
EP2717322A4 (en) | 2011-05-25 | 2015-01-21 | Hitachi Ltd | Solar cell |
US20120313205A1 (en) | 2011-06-10 | 2012-12-13 | Homayoon Haddad | Photosensitive Imagers Having Defined Textures for Light Trapping and Associated Methods |
US20140319524A1 (en) | 2011-12-09 | 2014-10-30 | University Of Florida Research Foundation, Inc. | Substrates having a broadband antireflection layer and methods of forming a broadband antireflection layer |
US20130215513A1 (en) | 2012-01-30 | 2013-08-22 | Guardian Industries Corp. | Method of making coated article including anti-reflection coating with porosity differences in two layers, and products containing the same |
GB201203183D0 (en) | 2012-02-24 | 2012-04-11 | Qinetiq Ltd | Optical multilayer |
DE102012105129A1 (en) | 2012-06-13 | 2013-12-19 | Christian-Albrechts-Universität Zu Kiel | Device for optical representation of intraocular pressure and method |
US9233883B1 (en) | 2013-03-15 | 2016-01-12 | Cornerstone Research Group, Inc. | Polymer composite comprising metal based nanoparticles in a polymer matrix |
US10700225B2 (en) | 2013-05-22 | 2020-06-30 | W&Wsens Devices, Inc. | Microstructure enhanced absorption photosensitive devices |
WO2015066337A1 (en) | 2013-10-31 | 2015-05-07 | University Of Florida Research Foundation, Inc. | Porous polymer membranes, methods of making, and methods of use |
WO2015116267A1 (en) | 2013-10-31 | 2015-08-06 | University Of Florida Research Foundation, Inc. | Substrates having an antireflection layer and methods of forming an antireflection layer |
EP3123211A4 (en) | 2014-03-25 | 2017-10-25 | Devos, John A. | Thin-film coating apparatus for applying enhanced performance coatings on outdoor substrates |
CN103935057B (en) | 2014-03-28 | 2017-06-13 | 中国科学院深圳先进技术研究院 | The preparation method of contact lenses and the method that intraocular pressure is monitored using contact lenses |
US9399720B2 (en) | 2014-07-14 | 2016-07-26 | Enki Technology, Inc. | High gain durable anti-reflective coating |
WO2016022661A1 (en) | 2014-08-05 | 2016-02-11 | University Of Washington | Three-dimensional printed mechanoresponsive materials and related methods |
US10189967B2 (en) | 2015-05-08 | 2019-01-29 | University Of Florida Research Foundation, Inc. | Macroporous photonic crystal membrane, methods of making, and methods of use |
CN105036068B (en) | 2015-06-17 | 2016-06-22 | 山东大学 | A kind of composite being suitable to low temperature alcohol sensor and application thereof |
US20170209045A1 (en) | 2016-01-26 | 2017-07-27 | California Institute Of Technology | System and method for intraocular pressure sensing |
US11467094B2 (en) | 2017-05-17 | 2022-10-11 | University Of Florida Research Foundation, Inc. | Methods and sensors for detection |
-
2019
- 2019-06-20 WO PCT/US2019/038193 patent/WO2019246370A1/en active Application Filing
- 2019-06-20 US US17/051,051 patent/US11819277B2/en active Active
-
2023
- 2023-10-02 US US18/375,595 patent/US20240023808A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11819277B2 (en) | 2023-11-21 |
WO2019246370A1 (en) | 2019-12-26 |
US20210186326A1 (en) | 2021-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Choritz et al. | Telemetric measurement of intraocular pressure via an implantable pressure sensor—12-month results from the ARGOS-02 trial | |
Koutsonas et al. | Implantation of a novel telemetric intraocular pressure sensor in patients with glaucoma (ARGOS study): 1-year results | |
Kohnen et al. | Effect of intraocular lens asphericity on quality of vision after cataract removal: an intraindividual comparison | |
Avadhanam et al. | Keratoprostheses for corneal blindness: a review of contemporary devices | |
Bélair et al. | Incidence of cystoid macular edema after cataract surgery in patients with and without uveitis using optical coherence tomography | |
Alió et al. | Clinical outcomes and intraocular optical quality of a diffractive multifocal intraocular lens with asymmetrical light distribution | |
Barathi et al. | Two models of experimental myopia in the mouse | |
Nanavaty et al. | Wavefront aberrations, depth of focus, and contrast sensitivity with aspheric and spherical intraocular lenses: fellow-eye study | |
US10123701B2 (en) | Intraocular pressure detecting device and detecting method thereof | |
Menzel-Severing et al. | Implantation and explantation of an active epiretinal visual prosthesis: 2-year follow-up data from the EPIRET3 prospective clinical trial | |
Orucoglu et al. | Analysis of age, refractive error and gender related changes of the cornea and the anterior segment of the eye with Scheimpflug imaging | |
Musch et al. | Factors associated with intraocular pressure before and during 9 years of treatment in the Collaborative Initial Glaucoma Treatment Study | |
Enders et al. | Telemetric intraocular pressure monitoring after Boston keratoprosthesis surgery using the Eyemate-IO sensor: dynamics in the first year | |
Pesudovs et al. | Effect of cataract surgery incision location and intraocular lens type on ocular aberrations | |
Alió et al. | Microincision multifocal intraocular lens with and without a capsular tension ring: optical quality and clinical outcomes | |
Alió et al. | Clinical outcomes and postoperative intraocular optical quality with a microincision aberration-free aspheric intraocular lens | |
Mansouri et al. | Short-Term and long-term variability of intraocular pressure measured with an intraocular telemetry sensor in patients with glaucoma | |
Enders et al. | Device profile of the EYEMATE-IO™ system for intraocular pressure monitoring: overview of its safety and efficacy | |
Szurman et al. | EYEMATE-SC trial: twelve-month safety, performance, and accuracy of a suprachoroidal sensor for telemetric measurement of intraocular pressure | |
Tahzib et al. | Higher-order aberrations after implantation of iris-fixated rigid or foldable phakic intraocular lenses | |
Siewert et al. | Development of a novel valve-controlled drug-elutable microstent for microinvasive glaucoma surgery: In vitro and preclinical in vivo studies | |
US11819277B2 (en) | Intraocular pressure sensing material, devices, and uses thereof | |
Gao et al. | Short-term reproducibility of intraocular pressure and ocular perfusion pressure measurements in Chinese volunteers and glaucoma patients | |
Mariacher et al. | Implantation and testing of a novel episcleral pressure transducer: A new approach to telemetric intraocular pressure monitoring | |
Kudrna et al. | Short-term steady-state pattern electroretinography changes using a multi-pressure dial in ocular hypertensive, glaucoma suspect, and mild open-angle glaucoma patients: a randomized, controlled, prospective, pilot study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHERWOOD, MARK B.;JIANG, PENG;WEBEL, AARON DAVID;SIGNING DATES FROM 20210528 TO 20210604;REEL/FRAME:065909/0091 |